ddn Online

The Blog of Drug Discovery News

Anacor throws its hat into IPO ring

Anacor Pharmaceuticals Inc. on Sept. 13 filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) of shares of its common stock, with a goal of selling up to $86.3 million in stock.

The Palo Alto, Calif.-based company had not, however, yet determined the number of shares to be offered nor the price range for the offering. All shares of the common stock to be sold in the offering, however, will be offered by Anacor.

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK ‘052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies’ research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.


September 13, 2010 Posted by | Corporate, Government | , | Leave a comment